Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply

Sandoz, a leading global pharmaceutical company, has issued a warning that the influx of low-cost antibiotic imports from China is jeopardizing the stability of Europe’s antibiotic supply. The company highlighted concerns that these cheaper alternatives could undermine the European pharmaceutical market, potentially leading to reduced investment in local production and innovation. This development poses risks to the availability and quality of essential antibiotics across the continent. The warning comes amid growing tensions in the pharmaceutical industry, where cost pressures and supply chain vulnerabilities have been exacerbated by the COVID-19 pandemic. Sandoz emphasized that reliance on inexpensive imports may compromise the resilience of Europe’s healthcare systems, especially given the strategic importance of antibiotics in combating bacterial infections and antimicrobial resistance. The company called for stronger regulatory measures and support for domestic manufacturing to safeguard the supply chain. Europe has long faced challenges in maintaining a robust pharmaceutical sector, with many manufacturers shifting production overseas to cut costs. The dominance of Chinese suppliers in the antibiotic market has intensified competition, often at the expense of quality standards and supply security. Experts warn that without intervention, this trend could lead to shortages and increased dependence on foreign sources, undermining public health preparedness. The situation underscores broader concerns about the globalization of pharmaceutical supply chains and the need for balanced policies that ensure affordability without compromising safety and innovation. Policymakers and industry stakeholders are urged to collaborate on strategies that protect Europe’s antibiotic supply, including incentives for local production, enhanced quality controls, and diversification of sourcing to reduce vulnerabilities.